Program
Leucovorin
Also written as “leucovorin”, “Folinic acid” and “FLOT Chemotherapy”.
Its studies are mostly in Colorectal Neoplasms · Neoplasms · Pancreatic Neoplasms · Carcinoma, Hepatocellular · Stomach Neoplasms, led by 21 companies.
Drug pageLeucovorin: every studyMany companies study it; this page follows only the 34 they lead. All 309 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sanofi | 50 open or running | phase 3since May 9, 2007 | May 9, 2007 | none ahead |
| AstraZenecaits history only | 41 open or running | phase 2since Jul 17, 2003 | Jul 17, 2003 | Nov 9, 2027phase 2 · NCT07069712 |
| Bristol-Myers Squibbits history only | 40 open or running | phase 2since Jun 26, 2002 | Jun 26, 2002 | none ahead |
| Hoffmann-La Rocheits history only | 30 open or running | phase 2since Feb 26, 2010 | Feb 26, 2010 | none ahead |
| Pfizerits history only | 21 open or running | phase 3since Sep 1, 2005 | Sep 1, 2005 | none ahead |
| 3SBioits history only | 11 open or running | phase 2since Jun 25, 2024 | Jun 25, 2024 | none ahead |
| AbbVieits history only | 11 open or running | phase 2since Oct 25, 2023 | Oct 25, 2023 | Dec 2026phase 2 · NCT06107413 |
| Adherex Technologiesits history only | 10 open or running | phase 2since Oct 27, 2010 | Oct 27, 2010 | none ahead |
| Aurobindo Pharmaits history only | 10 open or running | phase 2since Mar 28, 2014 | Mar 28, 2014 | none ahead |
| Cardiff Oncologyits history only | 10 open or running | phase 2since Feb 9, 2021 | Feb 9, 2021 | none ahead |
| Eli Lillyits history only | 10 open or running | phase 2since Jul 3, 2012 | Jul 3, 2012 | none ahead |
| Ipsenits history only | 10 open or running | phase 3since Sep 6, 2019 | Sep 6, 2019 | none ahead |
| Jiangsu HengRui Medicineits history only | 11 open or running | phase 3since Feb 20, 2023 | Feb 20, 2023 | none ahead |
| Leaf Verticalits history only | 10 open or running | phase 2since Jun 5, 2018 | Jun 5, 2018 | none ahead |
| Merck KGaA, Darmstadt, Germanyits history only | 10 open or running | phase 3since Dec 4, 2015 | Dec 4, 2015 | none ahead |
| Merrimack Pharmaceuticalsits history only | 10 open or running | phase 3since Dec 14, 2011 | Dec 14, 2011 | none ahead |
| Novartisits history only | 10 open or running | phase 1since Jan 4, 2011 | Jan 4, 2011 | none ahead |
| Oncolytics Biotechits history only | 10 open or running | phase 1since Jan 7, 2011 | Jan 7, 2011 | none ahead |
| Swedish Orphan Biovitrumits history only | 10 open or running | phase 2since Feb 14, 2006 | Feb 14, 2006 | none ahead |
| TTY Biopharmits history only | 10 open or running | phase 2since Apr 12, 2018 | Apr 12, 2018 | none ahead |
| Wellstat Therapeuticsits history only | 10 open or running | phase 1since Sep 4, 2002 | Sep 4, 2002 | none ahead |
Also a collaborator on its studies: Ono Pharmaceutical, Parexel, Halozyme Therapeutics, BioLineRx, Axis Clinicals and Regeneron Pharmaceuticals.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Sanofi only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 9, 2007First study: phase 3 study in Carcinoma, HepatocellularFirst studyNCT00471965 · 371 enrolled · China, Korea, Republic of, Taiwan and more
- Jul 10, 2007Phase 1 study in AdenocarcinomaNCT00499850 · 18 enrolled · Australia
- Nov 15, 2007Phase 2 study in Carcinoma, HepatocellularNCT00559455 · 38 enrolled · Korea, Republic of
- Oct 28, 2008Phase 2 study in Uterine NeoplasmsNCT00782041 · 11 enrolled · Thailand
- Aug 14, 2013Phase 1 study in NeoplasmsNCT01930552 · 20 enrolled · China
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 Sanofi leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT01930552Neoplasms · China | 1 | Completed | Dec 2014 | 20 |
| NCT00782041Uterine Neoplasms · Thailand | 2 | Terminated | Aug 2003 | 11 |
| NCT00559455Carcinoma, Hepatocellular · Korea, Republic of | 2 | Completed | Jan 2010 | 38 |
| NCT00499850Adenocarcinoma · Australia | 1 | Completed | Jun 2006 | 18 |
| NCT00471965Carcinoma, Hepatocellular · China, Korea, Republic of, Taiwan and more | 3 | Completed | Mar 2010 | 371 |
How it is read
Names in the registry
- “Leucovorin”, 18 entries
- “leucovorin”, 4 entries
- “Folinic acid”, 3 entries
- “FLOT Chemotherapy”, 1 entry
- “Folinic Acid”, 1 entry
Conditions, from the studies’ own filings
- Colorectal Neoplasms, 11 studies
- Neoplasms, 4 studies
- Pancreatic Neoplasms, 4 studies
- Carcinoma, Hepatocellular, 2 studies
- Stomach Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.